Status:
TERMINATED
Effectiveness of Protected Environment Rooms for AML and MDS
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
60+ years
Brief Summary
The goal of this clinical research study is to learn if the "protected environment" (PE) can help to prevent infections in patients aged 60 and above who are receiving what is considered low-intensity...
Detailed Description
For AML or high-risk MDS, it has been common practice for patients aged 50 and older to receive initial treatment in the PE at M. D. Anderson. The PE is a series of rooms containing a special air-flow...
Eligibility Criteria
Inclusion
- AML or high-risk MDS (\> 10% blasts in the marrow or blood)
- Patient is to be given "targeted therapy". Examples of targeted therapies are tipifarnib + low-dose ara-C, decitabine, and 5 azacitidine + valproic acid.
- Age \>/= 60 years and Zubrod performance status of 0,1, or 2
- Informed consent obtained
Exclusion
- Cannot receive ara-C at a dose \>/= 100 mg/m2 daily, anthracyclines, or cloretazine.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00443300
Start Date
January 1 2007
End Date
January 1 2008
Last Update
August 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030